Shares of Sophiris Bio Inc (NASDAQ:SPHS) ended Wednesday session in red amid volatile trading. The shares closed down -0.01 points or -0.35% at $2.86 with 628,712 shares getting traded. Post opening the session at $2.89, the shares hit an intraday low of $2.83 and an intraday high of $2.98 and the price vacillated in this range throughout the day. The company has a market cap of $83.57 million and the numbers of outstanding shares have been calculated to be 29.12 million shares.
Sophiris Bio Inc (SPHS) , a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companys primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) ended Wednesday session in red amid volatile trading. The shares closed down -3.02 points or -2.48% at $118.75 with 1,323,386 shares getting traded. Post opening the session at $122.04, the shares hit an intraday low of $118.59 and an intraday high of $122.10 and the price vacillated in this range throughout the day. The company has a market cap of $25.73 billion and the numbers of outstanding shares have been calculated to be 224.25 million shares.
Alexion Pharmaceuticals, Inc. (ALXN) announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength of those impacted by these diseases. Uncommon Strength (www.UncommonStrength.com) supports global rare disease communities, including those impacted by atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D) with educational information as well as interactive social media elements to unite the community.
People living with rare diseases, and their families, must demonstrate “uncommon strength” as they persevere to find answers about their diseases. Reaching a diagnosis for a rare disease can be a long and challenging experience because the conditions are often unknown, misunderstood, or misdiagnosed. In fact, the average time from a person’s first symptom to receiving an accurate diagnosis of a rare disease is nearly five years, during which he or she may visit more than seven physicians.